Page 557 - Read Online

Morgan et al. J Cancer Metastasis Treat 2018;4:46 I http://dx.doi.org/10.20517/2394-4722.2018.19 Page 13 of 13

40. Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer
metastatic phenotype in vitro. Mol Cancer Ther 2010;9:1554-61.
41. Fujiuchi Y, Nagakawa O, Murakami K, Fuse H, Saiki I. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol
Rep 2003;10:1001-6.
42. Davies G, Watkins G, Mason MD, Jiang WG. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in
vitro invasion and migration in prostate cancer cells. Prostate 2004;60:317-24.
43. Maitland NJ. Getting closer to prostate cancer in patients - what scientists should want from clinicians. J Cancer Metastasis Treat
2017;3:262-70.
44. Kondo A, Hashimoto S, Yano H, Nagayama K, Mazaki Y, Sabe H. A new paxillin-binding protein, PAG3/Papalpha/KIAA0400, bearing an
ADP-ribosylation factor GTPase-activating protein activity, is involved in paxillin recruitment to focal adhesions and cell migration. Mol
Biol Cell 2000;11:1315-27.
45. Li M, Wang J, Ng SS, Chan CY, He ML, Yu F, Lai L, Shi C, Chen Y, Yew DT, Kung HF, Lin MC. Adenosine diphosphate-ribosylation fac-
tor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation. Cancer 2009;115:4959-72.
46. Gaschet J, Hsu VW. Distribution of ARF6 between membrane and cytosol is regulated by its GTPase cycle. J Biol Chem 1999;274:20040-
5.